[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"long-covid19\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:long-covid19":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,69,98,135,159,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100631271","understanding-the-long-term-impact-of-covid-19-in-adults-100631271",false,"NCT07498504","Understanding the Long-term Impact of COVID-19 in Adults","RECOVER-Adult Cycle 2: A Long-Term Follow Up Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults","Inclusion Criteria:\n\n* RECOVER-Adult 2024 LCRI 11 or greater, as defined by Geng et al, 2024;1 or\n* At least 1 RECOVER-Adult LCRI symptom and either a) poor quality of life (QoL) as defined by a response of \"poor\" on the PROMIS-10 QoL question or b) \"bother scale\" is \"quite a bit\" or \"very much\" for corresponding LCRI symptom; or\n* At least 1 National Academies of Sciences, Engineering, and Medicine (NASEM) common symptom and either a) poor QoL, or b) \"bother scale\" is \"quite a bit\" or \"very much\" for corresponding NASEM symptom.\n\nExclusion Criteria:\n\n* Individuals who have a known or documented hemoglobin lower than 8.5 g\u002FdL,\n* Individuals who have not yet reached the age of majority,\n* Individuals who are unable to provide consent,\n* Individuals who are unwilling to consent to biospecimen collection or are unwilling to participate in the complete protocol, including all assessments and the cycle 2 visit schedule. Note that there are no exclusions related to blood volume collection. For healthy adults, the volume of blood collected (70.9 mL per visit and per year) is substantially lower than the federal minimal risk limit of 550 mL within 8 weeks,\n* Individuals in hospice care,\n* Individuals with a serious medical condition which would prevent in-person participation,\n* Individuals participating in the study NIH RECOVER-Pediatric: Understanding the long-term impact of COVID on children and families, unless enrolled only as caregiver, or\n* Long-term incarcerated individuals","ALL","18 Years","100 Years",{"count":20,"type":21},5205,"ESTIMATED","OBSERVATIONAL","Long COVID (LC) affects an estimated 5-10% of individuals with SARS-CoV-2 causing a persistent physical, cognitive, and functional impairment with potentially severe socioeconomic consequences. While RECOVER-Adult cycle 1 established the largest, most comprehensive U.S. adult LC cohort (14,730 participants), key questions remain about long-term disease trajectories, biological mechanisms, and late-emerging complications. RECOVER-Adult cycle 2 will follow selected participants for two years each, focusing on neurocognitive, cardiopulmonary and infection-associated chronic conditions (IACC) such as Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome (ME\u002FCFS) and autonomic dysfunction. Using a case-cohort design, the study will investigate disease persistence versus resolution, biological mechanisms, and onset of new chronic illnesses, generating critical insights to guide prevention, treatment, and public health policy.",[25,26],"Long COVID","Long Covid19","NOT_YET_RECRUITING","2026-03-23",{"date":30,"type":31},"2026-03-27","ACTUAL",{"date":33,"type":21},"2026-05",{"date":35,"type":21},"2030-04",{"name":37,"class":38},"NYU Langone Health","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":39},"100607544","phase-2-effect-of-2-hoba-in-persistent-immune-activation-in-long-covid-pots-100607544","NCT07189936","Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS","Mechanism of Isolevuglandin-Protein Adduct Formation in Persistent Immune Activation in Long COVID POTS","Inclusion Criteria:\n\nAll participants should meet diagnostic criteria for Long COVID and POTS and as outlined below:\n\nLong COVID (LC) is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection.\n\nPOTS: the presence of chronic symptoms lasting more than 3 months, along with orthostatic tachycardia (a HR increase over 30 bpm upon standing or exceeding 120 bpm without orthostatic hypotension) within 10 minutes upon standing or 75-degree head up tilt.\n\nFor patients aged 18 and 21, an increase of more than 40 bpm or a standing HR over 130 bpm will be required for inclusion in the study.\n\n2 Patients need confirmation of POTS diagnosis based on orthostatic vital signs obtained prior to enrollment in the study.\n\nSARS-CoV-2 infection 3 or more months prior identified by the follow signs:\n\nA. Meets the clinical OR epidemiological criteria.\n\n1. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness\u002Ffatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia.\n2. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presents with acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization); or C. Presents with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 antigen-Rapid Diagnostic Test.\n\nD. A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or E. Meeting clinical criteria AND\u002FOR epidemiological criteria (See A). With a positive professional use or self-test, SARS-CoV-2 Antigen-Rapid Diagnostic Test.\n\nF. Documented by health care provider in clinical note or encounter.\n\nExclusion Criteria:\n\n1. Known active acute SARS-Cov-2 infection (4 weeks from onset)\n2. Moderate or severe immunocompromised patients,\n3. Known history of cardiovascular disease (atrioventricular block (AV block), myocardial infarction, angina, heart failure, pacemaker, stroke, transient ischemic attack within 6 months before enrollment),\n4. Uncontrolled hypertension (BP\\>140\u002F90 despite appropriate treatment);\n5. Type 1 or type 2 diabetes mellitus;\n6. Impaired hepatic function (AST or ALT greater than 1.5x the upper limit of normal or with total bilirubin ≥1.5mg\u002Fdl),\n7. Impaired renal function test (eGFR\\\u003C60 mL\u002Fmin\u002F1.73m2),\n8. Anemia (hemoglobin \\\u003C10 g\u002Fdl),\n9. Pregnant or breastfeeding women,\n10. Known history of autoimmune disease, steroid use or other immunotherapies,\n11. Inability to provide informed consent.\n\nWe will also exclude individuals with known allergy sensitivity to components of the study medication, known contraindication to the study interventions, use of central acetylcholinesterase inhibitors (e.g., pyridostigmine, donezepil), aspirin allergy because salicylic acid is a metabolite of 2-HOBA; use of monoamine oxidase inhibitors (MAO-I) because of some inhibition of MAO-A is present in the anticipated therapeutic range of 2-HOBA.\n\n\\-",{"count":48,"type":21},50,"INTERVENTIONAL",[51],"PHASE2","Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID.\n\nLong COVID Postural Orthostatic Tachycardia Syndrome (LCPOTS) symptoms include fatigue, exercise intolerance, orthostatic intolerance, syncope, and heightened orthostatic tachycardia.\n\nResearch has found that decreased parasympathetic activity in LCPOTS increases the production of highly immunogenic neoantigens Isolevuglandins (IsoLG-adducts). IsoLG-adducts induce formation of circulating monocyte\u002FT cell complexes(doublets) leading to the persistent and unresolved immune response that continues after the initial infection.\n\nThe purpose of the this research, is to study the effects of 2-hydroxybenzylamine (2-HOBA), an Iso-LG-adduct scavenger, its effects in immune markers and compare it with Placebo",[54,55,56,57],"Post-Acute COVID-19 Syndrome","Postural Tachycardia Syndrome (POTS)","SARS CoV 2 Infection","Long COVID19",[25],"RECRUITING","2026-01-21",{"date":62,"type":31},"2026-01-22",{"date":64,"type":31},"2025-12-18",{"date":66,"type":21},"2029-06-30",{"name":68,"class":38},"Vanderbilt University Medical Center",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":49,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":39},"100603713","long-covid-19-alleviation-through-learning-mindfulness-study-100603713","NCT07140094","Long-Covid-19 Alleviation Through Learning Mindfulness Study","Long-Covid-19 Alleviation Through Learning Mindfulness Study (LONG-CALM)","LONG-CALM","Inclusion Criteria:\n\n* Age \\> or = 18\n* Willing and able to provide informed consent\n* Access to the internet\n* Self-reported history of SARS-CoV-2 infection\n* Current symptoms attributed to PASC by participant or by participant's medical provider; ongoing symptoms that persisted \\>= 12 weeks after Covid-19 illness\n\nExclusion Criteria:\n\n* Participating in another clinical trial of an intervention for PASC symptoms\n* Engaged in a structured MBI",true,{"count":79,"type":21},400,[81],"NA","This research is being done to study a mindfulness intervention among people who have symptoms of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Mindfulness is defined as paying attention to the present moment with non-judgment and acceptance. Here the investigators are studying whether a mindfulness intervention can help reduce stress, reduce Long COVID symptoms, and improve quality of life among people living with Long COVID. The mindfulness intervention is a series of recorded mindfulness sessions, which were created by the study team. People who decide to take part will be randomly assigned to receive the study mindfulness intervention immediately after joining the study or to receive the study mindfulness intervention 8 weeks after joining the study. All participants will continue their usual medical care. Participants will complete online surveys to measure symptoms over time. The study will last 6 months.",[25,26,84,54,85,86],"Post-Acute COVID-19","Post-Acute COVID-19 Infection","COVID Long-Haul",[88],"Covid","2025-08-21",{"date":91,"type":31},"2025-08-24",{"date":93,"type":31},"2024-05-21",{"date":95,"type":21},"2027-11-21",{"name":97,"class":38},"Columbia University",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":49,"phases":109,"briefSummary":110,"conditions":111,"keywords":115,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100557134","telerehabilitation-of-balance-clinical-and-economic-decision-support-system-100557134","NCT06534164","Telerehabilitation of Balance Clinical and Economic Decision Support System","TeleRehab DSS","ALL PARTICIPANT Inclusion Criteria:\n\n* Age 40-80 years\n* community dwelling able to walk 500-m independently or with a stick\n* Depression subscale on Hospital Anxiety and Depression Scale \\\u003C10\u002F21 (14-item questionnaire)\n* No significant visual impairment (as self-reported by participants)\n* Willing to comply with study procedures, proposed training and testing regime\n* With capacity to consent\n* No acute musculoskeletal or other injuries that would prevent participation in a structured exercise program\n* Is not currently, and has not in the past 8-weeks received any falls\u002Fbalance\u002Fvestibular and\u002For cognitive rehabilitation.\n* Does not any implanted medical devices or a cardiac pacemaker.\n* Does not have any other co-existing neurological conditions (ie. Multiple sclerosis, Parkinson's disease, neuropathy etc.)\n* Does not have any language or communication deficits impairing their ability to communicate and\u002For express their thoughts.\n* Has at least one functional hand for grip function and computer use.\n* Fulfilling all of the criteria from one of the below sub-groups\n\nSTROKE COHORT who will fulfil the additional criteria:\n\n* Individuals with diagnosis of focal ischaemic or haemorrhagic stroke, as confirmed by a clinical letter.\n* Onset \\>\u002F= 3 months prior to study.\n* Montreal Cognitive Assessment (MoCA) score n \\>\u002F=23\n* At risk of falls (i.e. Functional Gait Assessment FGA score \\\u003C\u002F=22\u002F30; FGA is a validated quick balance task assessment) AND\u002FOR having experienced a fall(s) in the last 12 months\n\nMCI COHORT who will fulfil the additional criteria:\n\n* Individuals with new or existing formal diagnosis of MCI, according to the International Classification of Disease 10 (ICD10) , as confirmed by a clinical letter.\n* At risk of falls (FGA \\\u003C\u002F= 22\u002F30) AND\u002FOR having experienced a fall(s) in the last 12 months.\n\nVESTIBULAR COHORT who will fulfill the additional criteria\n\n* Montreal Cognitive Assessment (MoCA) score n \\>\u002F=23\n* Individuals with a diagnosis of a vestibular disorder (peripheral and\u002For mixed peripheral and central):\n* Peripheral vestibular disorder in which the balance problem lies in the vestibular\u002Fbalance system within the inner ear.\n* Mixed vestibular disorder in which the balance problem lies in the vestibular\u002Fbalance system within the inner ear (peripheral) and involving the nerves or neuronal network in the brain\u002Fbrainstem responsible for balance (central).\n* Chronic dizziness and\u002For unsteadiness (\\>\u002F= 3 months duration) that started at the time or after the vestibular disorder diagnosis.\n* Dizziness handicap inventory (DHI \\>34) AND\u002FOR At risk of falls (FGA \\\u003C\u002F=22\u002F30)\n\nLONG COVID-19 COHORT who will fulfill the additional criteria:\n\n* Montreal Cognitive Assessment (MoCA) score n \\>\u002F=23\n* Individuals with laboratory confirmed diagnosis of Covid (\\>\u002F=6 months prior to study onset), as confirmed by a clinical letter.\n* Who have been diagnosed with long Covid, as confirmed by a clinical letter.\n* Who have chronic dizziness and\u002For unsteadiness which started after the Covid illness (self-report by the patient; duration \\\u003C\u002F=3 months).\n* Dizziness handicap inventory (DHI \\>34) AND\u002FOR At risk of falls (FGA \\\u003C\u002F=22\u002F30)\n\nExclusion Criteria:\n\n* Outside of the stated age bracket\n* Unable to walk independently (even with use of a walking stick)\n* MOCA score \\\u003C23\n* Score of 10 or higher on depression subscale of HADS\n* Unwilling to comply with study procedures, proposed training and testing regime\n* No capacity to consent\n* Significant visual impairment or homonymous hemianopia (stroke cohort only) (self-reported)\n* Orthostatic hypotension or uncontrolled hypertension\n* Other neurological problem (e.g. Parkingson's disease, Multiple Sclerosis etc.)\n* Language and communication deficits impairing ability to express thoughts (e.g. Aphasia)\n* Has participated in a clinical drug trial in the past 6 months.\n* Acute musculoskeletal injury that prevents participation in a structured exercise programme (e.g. lower limb fracture).\n* Has an implanted medical device or cardiac pacemaker.\n* Diagnosis of unstable Meniere's or with more than 4 migraines\u002Fmonth at the time of participating in the study\n* Not fulfilling the inclusion criteria for one of the sub-groups (such as criteria for Stroke group, or MCI group, or chronic vestibular disorder group, or long-Covid group), as outlined above.\n* Unable to provide a clinical letter confirming diagnosis.\n* For those with stroke, no visual spatial neglect.","40 Years","80 Years",{"count":108,"type":21},460,[81],"This study follows the successfully completed HOLOBalance project which was funded by the EU Horizon 2020 scheme. TheHOLOBalance platform delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. Further information is available at: https:\u002F\u002Fholobalance.eu\u002F. HOLOBalance was developed as a comprehensive rehabilitation protocol for individualised remote (tele)rehabilitation balance physiotherapy programme. It includes different multisensory balance and gait exercises, physical activity and memory training and exergames (video games which are also exercises) to improve balance function in older adults. The system can thus assess and remotely monitor how users are performing the exercises.\n\nThis multisite randomised control trial (TeleRehab DSS, short for TeleRehabilitation Decision Support System) aims to (i) determine the system's safety, acceptability, and feasibility explore effectiveness of running such programme in comparison with the current standard care for middle-age\u002Folder adults with balance disorders\u002Ffalls due to MCI, vestibular disorders, stroke or long Covid. This study also aims to (ii) assess if balance function, gait, cognitive function, balance confidence, and wellbeing can improve more compared to standard intervention and (iii) provide preliminary data for a definitive randomised controlled trial.\n\nThis study involves human participants, and each clinical site has applied for appropriate ethical approval.",[112,113,114,26],"Stroke","Mild Cognitive Impairment","Vestibular Diseases",[116,117,118,119,120,121,122,123,124],"vestibular","rehabilitation","falls","balance","exercise","artificial intelligence","telerehabilitation","physiotherapy","cognitive","2025-07-03",{"date":127,"type":31},"2025-07-10",{"date":129,"type":21},"2025-09-01",{"date":131,"type":21},"2026-08-31",{"name":133,"class":38},"University College, London",5,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":49,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":39},"100496198","the-long-covid-19-wearable-device-study-100496198","NCT05741112","The Long COVID-19 Wearable Device Study","Inclusion Criteria:\n\n* Is at least 18 years old.\n* Has a self\u002Fand or physician diagnosis of:\n* Long COVID (based on the WHO working definition),\n* ME\u002FCFS (myalgic encephalomyelitis \u002F chronic fatigue syndrome, self-diagnosis based on IOM criteria), and\u002For\n* POTS (Postural Orthostatic Tachycardia Syndrome).\n* Is interested in tools to manage ME\u002FCFS, POTS, and\u002For Long COVID symptoms.\n* Owns a wearable device they are willing to use for this study or does not own a device and agrees to utilize a study-provided one.\n* Agrees to wear the device throughout the study period, share the data with the study, and sync data at least weekly.\n* Has access to a smartphone or tablet to enable syncing wearable data and viewing device feedback.\n* Agrees to disclose involvement in other ME\u002FCFS, POTS, and\u002For Long COVID interventions such as medical treatment, self-management, and other interventional studies.\n* Agrees to complete at least 75% of the study surveys.\n\nExclusion Criteria:\n\n* As long as they meet inclusion there is no exclusion",{"count":142,"type":21},100500,[81],"To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.",[25,146,147,148,149,26],"Postural Orthostatic Tachycardia Syndrome","Dysautonomia","Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","2025-05-09",{"date":152,"type":31},"2025-05-11",{"date":154,"type":31},"2023-11-16",{"date":156,"type":21},"2025-12-01",{"name":158,"class":38},"Scripps Translational Science Institute",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":106,"enrollmentInfo":166,"targetDuration":4,"studyType":49,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":39},"100564783","acupuncture-for-post-covid-19-condition-long-covid-neuropsychiatric-symptoms-100564783","NCT06633666","Acupuncture for Post COVID-19 Condition (Long COVID) Neuropsychiatric Symptoms","Acupuncture for Long COVID Neuropsychiatric Symptoms: a Pragmatic,Randomized Clinical Trial","Inclusion Criteria:\n\n* meet the clinical diagnosis of Long COVID by the World Health Organization (WHO), with no neuropsychiatric symptoms 1 year before infection with Covid-19, and continue to have at least one neuropsychiatric symptom for 2 months after SARS-CoV-2 turned negative 3 months above;\n* aged 12 to 80 years;\n* willing and able to consent, and complete all assessment and study procedures\n\nExclusion Criteria:\n\n* patients with a history of chronic neuropsychiatric symptoms;\n* cardiovascular diseases pre-existing to the Covid-19 episode such as arrhythmia, heart failure, myocardial infarction, and patients with cardiac pacemakers;\n* documented pre-existing history of psychiatric illness, including substance abuse;\n* suicidal tendencies (attempted suicide in the 12 months before the study);\n* any chronic or remote neurological disorder (i.e. stroke, head trauma, epilepsy, tumor);\n* those who participated in other clinical trials within one month;\n* pregnant or lactating female patients;\n* have surgery within two months before the study or will have a scheduled surgery during the study;\n* acute brain injury or acute encephalopathy from another etiology than Covid-19 (e.g., sepsis, liver or renal failure, alcohol or drug withdrawal, drug toxicity);\n* open-heart cardiac surgery or cardiac arrest during the last 6 months;\n* patients who received acupuncture treatment 1 month before the start of the study;\n* patients who were unable to complete the assessment during screening due to severe mental, cognitive, or emotional impairment",{"count":167,"type":21},160,[81],"In this study, a 12-week pragmatic, randomized, double-blinded clinical trial will be conducted to evaluate the efficacy of acupuncture for the treatment of long Covid neuropsychiatric symptoms and provide reference for clinical non-drug treatment.",[26,171,172],"Neuropsychiatric Symptom","Acupuncture","2024-11-11",{"date":175,"type":31},"2024-11-13",{"date":177,"type":31},"2023-07-30",{"date":179,"type":21},"2026-04-30",{"name":181,"class":38},"Hong Kong Baptist University",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":77,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":188,"targetDuration":190,"studyType":22,"phases":4,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":39},"100484013","clinical-characteristics-and-long-term-impact-on-pediatric-covid-19-in-taiwan-100484013","NCT05582512","Clinical Characteristics and Long Term Impact on Pediatric COVID-19 in Taiwan","Inclusion Criteria:\n\n* COVID-19 positive cases\n\nExclusion Criteria:\n\n1. You have metal substances that cannot be removed or implanted, such as: braces, metal nails, artificial electronic ears, heartbeat pacemakers, etc. Because of the inability to perform brain MRI, it is not suitable to participate in this trial.\n2. Have major physical diseases.\n3. Sensory impairment, such as deafness.\n4. Movement disorders, such as cerebral palsy.\n5. Uncontrolled and stable epilepsy.\n6. Pregnant women are not suitable to participate in this test. (If you are pregnant or not sure if you are pregnant, please let the researcher know in advance so that a pregnancy test can be performed).\n7. Those who have suffered from hypoxia due to encephalitis or other reasons not caused by enterovirus infection are not suitable to participate in this test.",{"count":189,"type":21},3000,"1 Year","This project will study severe COVID-19 related factors, host genes, biomarkers, and prognosis of severe encephalitis in children, and conduct:\n\n1. Retrospective clinical analysis of children with COVID-19, to analyze the clinical manifestations of children with new crown infection, and to find the relevant factors of severe disease.\n2. Prospective acceptance in the acute phase: mainly to understand the correlation between the interaction of host factors, viruses and microorganisms and the severity.\n3. Children's long COVID-19 Tracking Team An integrated outpatient clinic for \"Long COVID-19 Syndrome in Children\" will be established to conduct systematic tracking of body, lung function, nerves and psychology. Children with neurological complications or other confirmed diagnoses will undergo physical, neurological, pulmonary function and brain MRI and neurophysiological examinations, sleep examinations, and conduct psychiatric clinical diagnostic interviews to establish a psychiatric diagnosis. Status and family social function, the intelligence development status was examined by intelligence test, and cognitive function was measured by neuropsychological test. Understand the microbial phase, immune function and incidence of allergic diseases after long-term new coronavirus infection.\n4. Seroepidemiological Study Group Exploring the seroepidemiology of different groups of health care workers and non-health care workers will allow us to better understand the magnitude of natural infection among children and age groups in the community and the infection profile of health care workers during this period.\n\nThis trial includes multiple groups of prospective cases to explore the impact of the new coronavirus on children and the mechanism of severe illness, and integrates various specialties and branches of the Children's Hospital to conduct a summary trial, which is expected to understand children's new crown and community epidemiology, children infected with new crown Clinical manifestations of the virus, risk factors and effects on various systems, combined with host microbiome, immune function analysis and whole-exome sequencing, to improve the detection of new coronavirus (including long-term new coronary syndrome and pediatric multisystem inflammatory syndrome). Mechanisms of host factors and interactions with microbes to improve outcomes and severe incidence in children.",[26,193,194],"COVID-19 Pneumonia","Multisystem Inflammatory Syndrome in Children",[196,197,198],"COVID-19","long COVID","MIS-C","2023-11-15",{"date":201,"type":31},"2023-11-18",{"date":203,"type":31},"2022-07-01",{"date":205,"type":21},"2027-12",{"name":207,"class":38},"National Taiwan University Hospital"]